Funding: None. 

Disclosures: RK received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K23HL153775) and the Doris Duke Charitable Foundation (under award 2022060). He also receives research support, through Yale, from Bristol-Myers Squibb. He is a coinventor of U.S. Provisional Patent Applications 63/177,117 and 63/346,610, unrelated to current work. He is also a founder of Evidence2Health, a precision health platform to improve evidence-based cardiovascular care. EKO is a co-inventor of the U.S. Provisional Patent Application 63/177,117, a co-founder of Evidence2Health, and reports a consultancy and stock option agreement with Caristo Diagnostics Ltd (Oxford, U.K.), all unrelated to the current work.